The estimated Net Worth of Timothy R Franson is at least $914 mil dollars as of 21 February 2023. Timothy Franson owns over 7,000 units of Cidara Therapeutics Inc stock worth over $836,640 and over the last 10 years he sold CDTX stock worth over $13,160. In addition, he makes $64,447 as Independent Director at Cidara Therapeutics Inc.
Timothy has made over 3 trades of the Cidara Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 7,000 units of CDTX stock worth $13,160 on 21 February 2023.
The largest trade he's ever made was selling 7,000 units of Cidara Therapeutics Inc stock on 21 February 2023 worth over $13,160. On average, Timothy trades about 750 units every 119 days since 2015. As of 21 February 2023 he still owns at least 72,000 units of Cidara Therapeutics Inc stock.
You can see the complete history of Timothy Franson stock trades at the bottom of the page.
Dr. Timothy R. Franson M.D. serves as Independent Director of the Company. Dr. Franson currently serves as a Principal in the Health and FDA Practice for FaegreDrinker Consulting. From April 2014 to July 2019, Dr. Franson served as the Chief Medical Officer of YourEncore, an advisory firm focused on global life sciences and consumer health companies. From 2009 until May 2014, he was principal of FaegreBD Consulting, a clinical and regulatory pharmaceutical development consulting form, which merged into Faegre Drinker Consulting in 2020. From 2008 until 2009, Dr. Franson served as the founder and president of Franson PharmaAdvisors LLC, a clinical and regulatory pharmaceutical development consulting firm. Prior to assuming these roles, Dr. Franson was vice president of Global Regulatory Affairs at Lilly Research Laboratories, a part of Eli Lilly and Company, at the time of his retirement in 2008, which he joined in 1986. Dr. Franson is integrally involved in global public health initiatives through the US Pharmacopeial Convention (USP), currently serving as the immediate past president of this organization and on the the USP Board of Trustees since 2010. He serves on the Board of Directors of Paratek Pharmaceuticals and as the Board Chair for the Critical Path Institute, which collaborates with FDA and industry in innovation advances. Dr. Franson has authored more than 50 articles in the fields of infectious disease, epidemiology, pharmacoeconomics, and antibiotic utilization. He holds a B.S. in pharmacy from Drake University and an M.D. from the University of Illinois College of Medicine. He is board certified in Internal Medicine and Infectious Diseases and Adjunct Professor of Medicine at Indiana University School of Medicine.
As the Independent Director of Cidara Therapeutics Inc, the total compensation of Timothy Franson at Cidara Therapeutics Inc is $64,447. There are 8 executives at Cidara Therapeutics Inc getting paid more, with Jeffrey Stein having the highest compensation of $1,451,970.
Timothy Franson is 68, he's been the Independent Director of Cidara Therapeutics Inc since 2015. There are 2 older and 16 younger executives at Cidara Therapeutics Inc. The oldest executive at Cidara Therapeutics Inc is Dr. Kenneth F. Bartizal Ph.D., 70, who is the Chief Devel. Officer.
Timothy's mailing address filed with the SEC is C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON, MA, 02116.
Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio... y Steve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
Cidara Therapeutics Inc executives and other stock owners filed with the SEC include: